Margaux Hall is a partner in the firm’s nationally recognized health care practice, based in Washington, D.C. Margaux is a leading lawyer in drug pricing, market access and value-based arrangements. She brings to clients an understanding of the transformative legal, policy, and changes affecting pricing, reimbursement, coverage and access to drugs, vaccines and devices.
Recognized by Chambers and other publications, Margaux provides sophisticated legal and strategic business counsel to clients – including pharmaceutical manufacturers, investors, and others – on regulatory matters, deals, and government enforcement matters. Her expertise spans topics of coverage and reimbursement under Medicare Advantage-Part D, Medicaid, the Federal Supply Schedule, and commercial payors; price reporting laws; and advising on the evolving landscape for drug development, pricing and commercialization in connection with the Inflation Reduction Act, Most Favored Nation proposals, and direct-to-patient market innovations.
Margaux’s deep knowledge of the pharmaceutical supply chain is invaluable in major life sciences transactions. Investors and others turn to Margaux to assist them in assessing and evaluating their investments in pharmaceutical products, specialty and long-term care pharmacies, pharmacy benefit managers, distributors, group purchasing organizations, patient support vendors, and other companies providing services to entities in the supply chain.
Margaux has dedicated her career to understanding health care in the U.S. and worldwide; after graduating from Harvard Law School, she pursued a Fulbright Fellowship to research health care law and health system reform in South Africa and then led similar research programs at the World Bank. Margaux also completed a post-graduate fellowship focusing on health law through Columbia Law School.